Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $72.66 and last traded at $72.66, with a volume of 11 shares traded. The stock had previously closed at $72.14.
Basilea Pharmaceutica Stock Performance
The company has a debt-to-equity ratio of 0.79, a current ratio of 6.32 and a quick ratio of 5.67. The company’s fifty day moving average is $64.82 and its 200 day moving average is $65.01.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital?treated diseases. The company’s research is focused primarily on anti?infectives and oncology, with a portfolio that spans both marketed products and early? to late?stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad?spectrum antifungal agent marketed under the trade name Cresemba.
See Also
- Five stocks we like better than Basilea Pharmaceutica
- Your Signature Is Missing – Act Before It’s Too Late
- Buy This Stock at 9:30 AM on MONDAY!
- What Expenses Can Be Deducted From Capital Gains Tax?
- The biggest scam in the history of gold markets is unwinding
- Your Bank Account Is No Longer Safe
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
